| Tarvacin (bavituximab) / OncXerna Therap |
2019-000949-13: A Study to investigate Bavituximab in combination with Pembrolizumab in patients with advanced gastric or gastroesophageal cancer. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Bavituximab, Pembrolizumab, NA, Solution for infusion, Solution for injection, Keytruda | OncXerna Therapeutics, Inc., OncXerna Therapeutics, Inc. | Advanced gastric or gastroesophageal cancer that progressed on or after at least one prior standard therapy, Advanced gastric or gastroesophageal junction cancer that progressed on or after at least one prior standard therapy., Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 80 | Europe, US, RoW | Bavituximab, Pembrolizumab Injection, Keytruda | OncXerna Theraputics, Inc., Merck Sharp & Dohme LLC | Gastric Cancer, GastroEsophageal Cancer | 12/21 | 10/22 | | |
NCT03139916: Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma |
|
|
| Completed | 2 | 36 | US | Temozolomide, Temodar, Bavituximab, Radiation | Massachusetts General Hospital, Peregrine Pharmaceuticals, National Comprehensive Cancer Network | Glioblastoma | 08/22 | 08/22 | | |
NCT03519997: A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 35 | US | Pembrolizumab, Bavituximab | David Hsieh, Merck Sharp & Dohme LLC | Hepatocellular Carcinoma | 04/23 | 04/25 | | |
NCT04150900: 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck |
|
|
| Active, not recruiting | 2 | 7 | US | Bavituximab, Pembrolizumab | University of Maryland, Baltimore | Squamous Cell Carcinoma | 01/25 | 01/27 | | |
